| MOPEE10 | What men want: preferences for pre-exposure prophylaxis for HIV among men who have sex with men in 16 countries in the Asia-Pacific: a discrete choice experiment | Poster exhibition | Implementation science and scale up of prevention |
| EPE0869 | What drives gaps in viral load monitoring and re-suppression after treatment failure? A multi-state analysis examining contributing client and provider behaviours in Zambia | E-poster | Implementation science and scale up of treatment |
| TUPED02 | What do we know about bisexual behaviours and condomless sex with women among men who have sex with men in Sub-Saharan Africa? A systematic review and meta-analysis | Poster exhibition | Key populations and other vulnerable populations: Behavioural, social and cultural issues and contexts |
| EPB0163 | What are the predictors of change in multimorbidity among people with HIV? A longitudinal observational cohort study | E-poster | Co-morbidities |
| EPB0199 | Weight gain and lipid changes with switching from boosted protease inhibitor-based regimens to bictegravir/tenofovir alafenamide/emtricitabine | E-poster | Clinical complications of HIV and antiretroviral therapy |
| MOPEB19 | Weight gain among people living with HIV in Zambia transitioning to dolutegravir-based antiretroviral regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate | Poster exhibition | Clinical complications of HIV and antiretroviral therapy |
| EPB0235 | Weight change and metabolic assessment of virologically suppressed children with HIV aged ≥2 years and weighing 14 to <25 kg who received a TAF-containing regimen | E-poster | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| OAB0203 | Weight and body composition after switch to doravirine/islatravir (DOR/ISL) 100/0.75mg once daily: week 48 results from 2 randomized active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) | Oral abstract session with live Q&A | Clinical complications of HIV and antiretroviral therapy |
| LBEPB13 | Week-96 results of ALLIANCE, a phase 3, randomized, double-blind study comparing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in treatment-naïve people with both HIV-1 and hepatitis B | E-poster | Co-infections (including opportunistic infections) |
| EPC0513 | W96 results of the OPTICARE program (France), an implementation program to optimize care among vulnerable persons living with HIV (PLWH) in virological failure (VF) | E-poster | Cascades of HIV care and treatment |